Combined 177 Lu-PSMA-617 PRLT and abiraterone acetate versus 177 Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.

Sonam SumanRahul V ParghaneAmit JoshiKumar PrabhashSanjay TaloleSandip Basu

Published in: The Prostate (2021)

In the present study, the combination of 177 Lu-PSMA-617 PRLT and AA therapy showed significant improvement in mCRPC patients' symptomatic response, PFS, and OS as compared to 177 Lu-PSMA-617 PRLT monotherapy.

Keyphrases

pet ct
pet imaging
end stage renal disease
chronic kidney disease
newly diagnosed
squamous cell carcinoma
combination therapy
small cell lung cancer
peritoneal dialysis
prognostic factors
computed tomography
bone marrow
replacement therapy